OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
Article
Bell, EH, Zhang, P, Aldape, K et al. (2017). OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
. NEURO-ONCOLOGY, 19(suppl_3), iii2-iii3. 10.1093/neuonc/nox036.006
Bell, EH, Zhang, P, Aldape, K et al. (2017). OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
. NEURO-ONCOLOGY, 19(suppl_3), iii2-iii3. 10.1093/neuonc/nox036.006